Results 121 to 130 of about 7,605 (170)

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [PDF]

FEBS Open Bio
Tsuda K, Ogino Y, Sato A.
europepmc   +1 more source

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

JAMA Netw Open
Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami U.   +17 more
europepmc   +1 more source

The 5' Cap Epitranscriptome and Beyond: Natural and Engineered 5' Cap Modifications for Optimizing mRNA Therapeutics and Functional Studies. [PDF]

ChemMedChem
Dahm GC, Pieper M, Schepers H, Rentmeister A.   +3 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. [PDF]

Ther Adv Med Oncol
Peng X, Song R, Fan Y, Wang J, Li Q, Mo H, Wang J, Luo Y, Chen S, Sun X, Zhang J, Zhang P, Xu B, Lan B, Ma F.   +14 more
europepmc   +1 more source

Protocol for synthesizing and purifying short-length poly(ADP)ribose polymer using fast protein liquid chromatography. [PDF]

STAR Protoc
Neeharika S, Hanuman DS, Rajakumara E.
europepmc   +1 more source

Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification. [PDF]

J Gynecol Oncol
Kim JH, Kim DE, Kim U, Bae JK, Jin WH, Park SY, Lim MC.   +6 more
europepmc   +1 more source

Molecularly Targeted Cancer Medications and Kidney Health.

JAMA Netw Open
Ziolkowski S, Long J, Zhong Y, Morgan-Cooper H, Wakelee H, Khaki A, Riaz F, Reddy S, Leonard M, Anand S.   +9 more
europepmc   +1 more source

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiriadis A, Heinzelmann-Schwarz V, Zwimpfer TA.   +18 more
europepmc   +1 more source

Purification and Properties of Poly (Adenosine Diphosphate Ribose) Synthetase

Purification and Properties of Poly (Adenosine Diphosphate Ribose) Synthetase
openaire  

Some of the next articles are maybe not open access.

Related searches:

Changes in poly(adenosine diphosphate-ribose) and poly(adenosine diphosphate-ribose) polymerase in synchronous HeLa cells

Biochemistry, 1976
An antibody has been prepared which is highly specific for poly(adenosine diphosphate-ribose). Neither poly(A), DNA, nor a variety of adenine-containing nucleosides or nucleotides were effective in competing with poly(ADP-ribose) for binding to the antibody. Of all compounds tested, only adenosine diphosphate-ribose competed for binding to the antibody.
W R Kidwell
exaly   +3 more sources